| __timestamp | Ascendis Pharma A/S | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 17986000 |
| Thursday, January 1, 2015 | 9415000 | 32480000 |
| Friday, January 1, 2016 | 11504000 | 68081000 |
| Sunday, January 1, 2017 | 13482000 | 169906000 |
| Monday, January 1, 2018 | 25057000 | 248932000 |
| Tuesday, January 1, 2019 | 48473000 | 354100000 |
| Wednesday, January 1, 2020 | 76669000 | 433300000 |
| Friday, January 1, 2021 | 160180000 | 583300000 |
| Saturday, January 1, 2022 | 221227000 | 752700000 |
| Sunday, January 1, 2023 | 264410000 | 887600000 |
| Monday, January 1, 2024 | 284545000 | 1007200000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing expenses is crucial for sustaining growth and innovation. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Neurocrine Biosciences, Inc. and Ascendis Pharma A/S from 2014 to 2023. Over this period, Neurocrine Biosciences has consistently outpaced Ascendis Pharma in SG&A spending, reflecting its aggressive market strategies and expansion efforts. By 2023, Neurocrine's SG&A expenses surged to nearly 890% of their 2014 levels, while Ascendis Pharma's expenses grew by approximately 420%. This stark contrast highlights Neurocrine's commitment to scaling its operations and enhancing its market presence. As these companies continue to evolve, their financial strategies will play a pivotal role in shaping their future trajectories. Investors and industry watchers should keep a close eye on how these expenses translate into market performance and innovation.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Catalyst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ascendis Pharma A/S
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation